Relmada Therapeutics Inc (RLMD) 2.1500 $RLMD Relmada

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Relmada Therapeutics Inc (RLMD) 2.1500 $RLMD

Relmada Therapeutics Secures First European Patent Covering LevoCap ER
PR Newswire - Wed Jul 06, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it has been granted a patent from the European Patent Office (EPO) for compositions and methods of use for its extended release oral levorphanol (3-hydroxy-N-methylmorphinan). The Patent (EP 2 448 406 B1), titled "Extended Release Oral Pharmaceutical Compositions of 3-hydroxy-N-methylmorphinan" broadly covers Relmada's SECUREL(TM) technology platform and LevoCap ER (REL-1015, levorphanol extended-release, abuse deterrent capsules). The patent is not scheduled to expire until 2030.

Relmada Therapeutics' d-Methadone Receives Orphan Drug Designation for Management of Postherpetic Neuralgia
PR Newswire - Tue Jun 07, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that d-Methadone (dextromethadone, REL-1017), a N-methyl-d-aspartate (NMDA) receptor antagonist in development as a treatment for both depression and chronic neuropathic pain, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia. Postherpetic neuralgia (PHN) is a painful neuropathic condition resulting from an outbreak of the herpes zoster virus, otherwise known as shingles.

Relmada Therapeutics to Present at the LD Micro Invitational Conference
PR Newswire - Wed Jun 01, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the LD Micro Invitational Conference on Tuesday, June 7, 2016 at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.

OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.

Relmada Therapeutics to Present at the 5th Annual Marcum MicroCap Conference
PR Newswire - Thu May 26, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City at the Grand Hyatt Hotel.

Relmada Therapeutics Announces Promotion of Michael D. Becker to Chief Financial Officer
PR Newswire - Mon May 16, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the promotion of Michael D. Becker to chief financial officer, effective as of May 11, 2016.

Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects
PR Newswire - Wed May 04, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the results of an in vivo study showing that administration of d-Methadone (REL-1017), a N-methyl-d-aspartate (NMDA) receptor antagonist, results in antidepressant-like effects. Results are shown to be comparable to those achieved in similar treatment models using ketamine.

Relmada Therapeutics to Present at the Joseph Gunnar "Pioneers 2016" Conference
PR Newswire - Thu Apr 28, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will present at the Joseph Gunnar "Pioneers 2016" Conference on May 5, 2016 at the New York Palace Hotel in New York City.

Relmada Therapeutics Provides Additional Details Regarding Upcoming R&D Day
PR Newswire - Tue Apr 26, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it will hold its first R&D Day on May 4, 2016, from 10:00 a.m. to 12:00 p.m.

Relmada Therapeutics' Michael Becker Interviewed by The Life Sciences Report
Marketwired - Thu Apr 21, 8:02AM CDT
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. (OTCQB: RLMD) has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.

Relmada Therapeutics, Inc. Provides Update on Nasdaq Up-Listing Process
PR Newswire - Thu Apr 14, 7:30AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, today provided investors with an update regarding the Company's qualification for up-listing to The Nasdaq Capital Market ("Nasdaq". As previously disclosed, the Company submitted an initial listing application with Nasdaq in the second half of 2015. The Company now believes that it satisfies each of the exchange's applicable listing requirements, with the exception of the $4.00 bid price requirement. In accordance with the Nasdaq Listing Rules, the Company's stock price must close at or above $4.00 per share for 30 of the most recent 60 trading days in order for the Company to be eligible to list.

UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.82 (-0.01), DMPI: 8.08 (-0.02), CDXC: 4.03 (-0.01)

OTCQX And OTCQB Companies To Present At 2016 ROTH Conference
PR Newswire - Thu Mar 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.82 (-0.01), DMPI: 8.08 (-0.02), CDXC: 4.03 (-0.01)

Relmada Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the Company will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8th at 3:30 p.m. Eastern Time. The conference will take place at the Waldorf Astoria Hotel in New York City.

Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern
PR Newswire - Tue Jan 26, 6:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a motion to amend its complaint against Laidlaw & Company (UK) Ltd. ("Laidlaw" in the U.S. District Court for the District of Nevada. The motion to file an amended complaint is part of the lawsuit that the Company had previously filed in the Nevada District Court. The amended complaint includes an additional legal claim based on Laidlaw's breach of the fiduciary duty that it owed to Relmada when Laidlaw disclosed confidential information that it acquired in its capacity as the Company's investment banker. Relmada is also seeking monetary damages arising from fees and costs that it incurred responding to Laidlaw's false and misleading proxy materials in December 2015.

Relmada Therapeutics Selected to Present at 2016 Biotech Showcase(TM) in San Francisco
PR Newswire - Mon Jan 11, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has been selected to present at the 8th Annual Biotech Showcase(TM) Conference at 2:00 PM Pacific Time (5:00 PM Eastern Time) on Wednesday, January 13, 2016. The presentation will take place in Track C - Mission II at the Parc 55 Hotel in San Francisco.

Relmada Therapeutics Successfully Completes Multiple Ascending Dose Study of d-Methadone for Neuropathic Pain
PR Newswire - Mon Jan 04, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it completed its multiple ascending dose ("MAD" study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate ("NMDA" receptor antagonist being developed for the treatment of neuropathic pain. Relmada previously completed a single ascending dose ("SAD" study in March 2015. The design of the Company's Phase II proof-of-concept study in neuropathic pain, anticipated to start in the first half of 2016, will be based on this study's findings.

Relmada Therapeutics Announces Results of Annual Meeting of Stockholders
PR Newswire - Wed Dec 30, 10:55AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or "the Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that, at the Company's 2015 Annual Meeting of Stockholders, Relmada stockholders voted to elect all of Relmada's director nominees: Shreeram Agharkar, PhD, and Maged Shenouda, R. Ph., MBDA. The final tabulation indicates that more than 94% of votes cast at the Annual Meeting were in support of Messrs. Agharkar and Shenouda.

Relmada Therapeutics Recommends Stockholders Vote "FOR" Relmada's Director Nominees on the WHITE Proxy Card Today
PR Newswire - Mon Dec 28, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, today reiterated its Board's unanimous recommendation that stockholders vote "FOR" the Company's highly qualified, independent director nominees - Shreeram Agharkar, PhD, and Maged Shenouda R. Ph., MBA - on the WHITE proxy card today.

U.S. Federal Court Grants Preliminary Injunction Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern
PR Newswire - Wed Dec 23, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company", a clinical-stage company developing novel therapies for the treatment of chronic pain, announced that following a hearing, the U.S. District Court for the District of Nevada granted Relmada's request and granted a Preliminary Injunction against Laidlaw & Company (UK) Ltd. and its principals, Matthew Eitner and James Ahern. The Court Order enjoins Laidlaw and Messrs. Eitner and Ahern from "continuing to disseminate false and misleading proxy materials."

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 89

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 63

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 99

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 97

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 36

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 16

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 50

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 63

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 54

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover AM Best's New Bookstore for Insurance Insights

Updated Category News Views 92

AM Best Unveils Innovative Bookstore for Insurance Readers AM Best recently launched the AM Best’s Bookstore, a unique digital platform designed for those interested in deeper insights into the insurance sector. This bookstore serves as a central hub for information on newly published books that cover a wide range of topics pertinent to the insurance industry....

Continue Reading
Aurora Mobile Hits a Milestone with Strong Q2 Financials

Updated Category News Views 174

Aurora Mobile Reports Impressive Second Quarter Financial Results Aurora Mobile Limited, recognized for its customer engagement and marketing technology services, has revealed its financial metrics for the second quarter of 2025. This quarter has marked a groundbreaking achievement with the company recording its inaugural quarterly net income under U.S. GAAP. Financial...

Continue Reading
Meta Platforms' Competitive Edge in Media and Services Sector

Updated Category News Views 279

Understanding Meta Platforms in its Industry Context In the fast-paced realm of Interactive Media & Services, comprehensive analysis is vital for both investors and market analysts. This article dives into an industry comparison, focusing on Meta Platforms (NASDAQ: META) along with its prominent competitors. By evaluating crucial financial indicators, market standings,...

Continue Reading
Investigation by Rosen Law Firm for Kaspi.kz Investors

Updated Category News Views 88

Rosen Law Firm's Investigation of Kaspi.kz Security Claims The Rosen Law Firm, globally recognized for protecting investor rights, has launched an investigation regarding potential securities claims for shareholders of Joint Stock Company Kaspi.kz (NASDAQ: KSPI). This investigation stems from serious allegations that Kaspi.kz may have disseminated misleading business...

Continue Reading
Praxis Precision Medicines to Showcase Innovations This Fall

Updated Category News Views 158

Upcoming Investor Conferences for Praxis Precision Medicines Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a dynamic entity in the field of biopharmaceuticals, has an exciting roster of events lined up this fall. The company is dedicated to developing therapies aimed at addressing central nervous system (CNS) disorders that are driven by imbalances in neuronal...

Continue Reading